TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17352519

Group type: EXPERIMENTAL
Intervention: Capecitabine plus cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pooled capecitabine-based regimens
Number of subjects: 0
Study: 14762352

Group type: EXPERIMENTAL
Intervention: Right coronary artery grafting
Number of subjects: 303

Group type: COMPARATOR
Intervention: No right coronary artery grafting
Number of subjects: 303
Study: 11750894

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9580647

Group type: EXPERIMENTAL
Intervention: Intranasal live attenuated, cold-adapted, trivalent influenzavirus vaccine (one dose)
Number of subjects: 1602

Group type: EXPERIMENTAL
Intervention: Intranasal live attenuated, cold-adapted, trivalent influenzavirus vaccine (two doses)
Number of subjects: 1602

Group type: EXPERIMENTAL
Intervention: Intranasal live attenuated, cold-adapted, trivalent influenzavirus vaccine (both regimens)
Number of subjects: 1602

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1602

Group type: EXPERIMENTAL
Intervention: Intranasal live attenuated, cold-adapted influenzavirus vaccine
Number of subjects: 1602
Study: 8072261

Group type: EXPERIMENTAL
Intervention: Dipyridamole alone
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Dipyridamole and aspirin combination
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Dipyridamole and aspirin
Number of subjects: 107
Study: 2647156

Group type: EXPERIMENTAL
Intervention: Intravenous amphetamine infusion (0.3 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 4889238

Group type: EXPERIMENTAL
Intervention: lincomycin hydrochloride (Mycivin)
Number of subjects: 22

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study: 30670760

Group type: EXPERIMENTAL
Intervention: 1,000 ppm SAPM
Number of subjects: 0

Group type: COMPARATOR
Intervention: 22,600 ppm fluoride varnish
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control, no treatment
Number of subjects: 0
Study: 28719765

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BTJ)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sodium nitrate (SN)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isocaloric placebo (PLA)
Number of subjects: 30
Study: 26015557

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) - categorized as PA0 (inactive), PA1 (one to two times per week), PA2 (more than two times per week)
Number of subjects: 18028

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 18028
Study: 24279607

Group type: EXPERIMENTAL
Intervention: Platelet pellet (PP) plus bioabsorbable barrier membrane (BM)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Bioactive glass (BG) graft material with barrier membrane (BM)
Number of subjects: 11
Study: 23095869

Group type: EXPERIMENTAL
Intervention: TUTI-16 vaccine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 19235040

Group type: EXPERIMENTAL
Intervention: 40 mg isoflavones daily
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 140 mg isoflavones daily
Number of subjects: 34
Study: 17702736

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of Aliskiren 150 mg and Valsartan 160 mg
Number of subjects: 12
Study: 15380898

Group type: EXPERIMENTAL
Intervention: Magnesium loading test in treated CD patients
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Magnesium loading test in untreated CD patients
Number of subjects: 77

Group type: COMPARATOR
Intervention: Magnesium loading test in control group
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Serum magnesium concentration
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Erythrocyte magnesium concentration
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Magnesium intake
Number of subjects: 77
Study: 11465977

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibuprofen 400 mg
Number of subjects: 0
Study: 9813387

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg, clarithromycin 250 mg and metronidazole 400 mg (OCM) given three times daily for 10 days
Number of subjects: 157

Group type: COMPARATOR
Intervention: Omeprazole 20 mg and amoxicillin 1 g (OA) given twice daily for 14 days
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: OCM group
Number of subjects: 157

Group type: COMPARATOR
Intervention: OA group
Number of subjects: 157
Study: 8569256

Group type: EXPERIMENTAL
Intervention: Water injection at Qimen, Riyue, and Juque points
Number of subjects: 56

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 56
Study: 2146870

Group type: EXPERIMENTAL
Intervention: 12-lead QRS voltage sum
Number of subjects: 1588

Group type: EXPERIMENTAL
Intervention: Sokolow-Lyon index
Number of subjects: 1588

Group type: EXPERIMENTAL
Intervention: ST-T alterations
Number of subjects: 1588
Study: 747689

Group type: EXPERIMENTAL
Intervention: Enflurane at subanaesthetic concentration of 0.25% (end‐tidal)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study: 31081030

Group type: EXPERIMENTAL
Intervention: Electronic mental health stigma intervention (brief contact interventions over a 6-week period)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 0
Study: 31100070

Group type: EXPERIMENTAL
Intervention: Institutional delivery care
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Health center delivery
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Maternal education
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Knowledge of obstetric complications
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Experience of complications during last birth
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Health centers vs health posts
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Motorized transportation availability
Number of subjects: 459
Study: 28615622

Group type: EXPERIMENTAL
Intervention: Optimized measurement order of the Hadamard basis using deterministic acquisition for single-pixel imaging.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional compressed sensing techniques (randomized sampling).
Number of subjects: 0
Study: 26314625

Group type: EXPERIMENTAL
Intervention: NBP607 (cell culture-derived inactivated trivalent influenza vaccine)
Number of subjects: 1156

Group type: COMPARATOR
Intervention: Control vaccine (AgrippalS1, egg-based subunit vaccine)
Number of subjects: 1156
Study: 24820759

Group type: EXPERIMENTAL
Intervention: Left atrial mono‐polar radiofrequency ablation
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Bi‐atrial mono‐polar radiofrequency ablation
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (valve replacement followed by amiodarone)
Number of subjects: 210
Study: 22746145

Group type: EXPERIMENTAL
Intervention: Therapist and patient alliance ratings
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Session progress ratings
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Therapist experience
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Psychosocial circumstances at treatment start
Number of subjects: 203
Study: 19535679

Group type: EXPERIMENTAL
Intervention: Glucose solution (500-ml intragastric infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fructose solution (500-ml intragastric infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspartame solution (500-ml intragastric infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saccharin solution (500-ml intragastric infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sweeter glucose + saccharin solution (500-ml intragastric infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinine solution (500-ml intragastric infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naringin solution (500-ml intragastric infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water (volumetric control)
Number of subjects: 0
Study: 17525598

Group type: EXPERIMENTAL
Intervention: Continuous intrawound infusion with 300 mg diclofenac
Number of subjects: 92

Group type: COMPARATOR
Intervention: Saline infusion with systemic diclofenac (75 mg IV every 12 h for 48 h)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Local ropivacaine infusion with systemic diclofenac (75 mg IV every 12 h for 48 h)
Number of subjects: 92
Study: 15341554

Group type: EXPERIMENTAL
Intervention: ba wei di huang wan (BDW)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 11588535

Group type: EXPERIMENTAL
Intervention: Manidipine (10-20 mg, once daily)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Amlodipine (5-10 mg, once daily)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Manidipine (ITT population)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Amlodipine (ITT population)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Manidipine
Number of subjects: 241

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 241
Study: 9681776

Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 112

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 112
Study: 8136506

Group type: EXPERIMENTAL
Intervention: Goldberg Scale
Number of subjects: 21
Study: 2402413

Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg)
Number of subjects: 20
Study: 606789

Group type: EXPERIMENTAL
Intervention: Killed split or whole bivalent influenza vaccine (A/New Jersey/76-A/Victoria/75)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 31755809

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVR) 0.5 mg
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVA) 2.0 mg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 96
Study: 30973651

Group type: EXPERIMENTAL
Intervention: BMI + Substance-Free Activity Session (SFAS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMI + Relaxation Training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMI + SFAS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-session BMI
Number of subjects: 0

Group type: COMPARATOR
Intervention: e-Chug
Number of subjects: 0

Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 0
Study: 27535276

Group type: EXPERIMENTAL
Intervention: Leech therapy (5 leeches applied to the affected knee, once every week for 3 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: TENS therapy
Number of subjects: 90
Study: 25987441

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamin supplementation (AVS) [vitamins C (500 mg), E (400 IU), beta‐carotene (15,000 IU), zinc (7.5 mg), selenium (50 mg), copper (1 mg), and manganese (2.5 mg)] for 4 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study: 22776518

Group type: EXPERIMENTAL
Intervention: Early oral intake within 5 days postoperatively
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late oral intake starting from postoperative day 6
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early oral intake
Number of subjects: 0
Study: 22115622

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Cobalt-chromium bare-metal stent (BMS)
Number of subjects: 1500
Study: 19571713

Group type: EXPERIMENTAL
Intervention: Trainee participation
Number of subjects: 368

Group type: COMPARATOR
Intervention: Experienced physician-only procedures
Number of subjects: 368
Study: 16940981

Group type: EXPERIMENTAL
Intervention: Pemetrexed (300 to 1,200 mg m(‐2) with FA/VB(12))
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pemetrexed (with FA/VB(12))
Number of subjects: 31
Study: 16823517

Group type: EXPERIMENTAL
Intervention: Track embolization
Number of subjects: 43

Group type: COMPARATOR
Intervention: No track embolization (Control)
Number of subjects: 43
Study: 14573830

Group type: EXPERIMENTAL
Intervention: Support and training from a health adviser in the management of C trachomatis for clinical staff for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 10569685

Group type: EXPERIMENTAL
Intervention: Postmeal walking exercise
Number of subjects: 0
Study: 8707913

Group type: EXPERIMENTAL
Intervention: Pure hyperactive (HA) group
Number of subjects: 1479

Group type: EXPERIMENTAL
Intervention: Mixed hyperactive/conduct-disordered (HA + CD) group
Number of subjects: 1479

Group type: EXPERIMENTAL
Intervention: Pure conduct-disordered (CD) group
Number of subjects: 1479

Group type: COMPARATOR
Intervention: Normal (N) control group
Number of subjects: 1479
Study: 1897349

Group type: EXPERIMENTAL
Intervention: Electrostimulation anaesthesia (ESA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Neurolept anaesthesia (NLA)
Number of subjects: 100
Study: 7088627

Group type: EXPERIMENTAL
Intervention: Loaner restraint seat offered with staff demonstration at discharge
Number of subjects: 30

Group type: COMPARATOR
Intervention: No loaner restraint seat and no emphasis on car safety
Number of subjects: 30
Study: 29072514

Group type: EXPERIMENTAL
Intervention: Chamomile extract (5 drops, three times a day for 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (5 drops, three times a day for 8 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chamomile extract
Number of subjects: 60
Study: 28388933

Group type: EXPERIMENTAL
Intervention: HbA1c test and brief standardized counseling
Number of subjects: 315

Group type: COMPARATOR
Intervention: Brochure about clinical preventive services
Number of subjects: 315
Study: 26164495

Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole, twice daily for 4 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole, twice daily for an additional 4 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Functional analysis during PPI use
Number of subjects: 12
Study: 24131496

Group type: EXPERIMENTAL
Intervention: IMPACT Therapy (HPI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 21960073

Group type: EXPERIMENTAL
Intervention: Isoflurane (MAC=0.8‐1) and N(2)O 50%
Number of subjects: 60

Group type: COMPARATOR
Intervention: TIVA (propofol at 100‐150 mg/kg/min and remifentanil at 2.0 mg/kg/min)
Number of subjects: 60
Study: 17880950

Group type: COMPARATOR
Intervention: Low dose step‐up regimen
Number of subjects: 225

Group type: COMPARATOR
Intervention: Step‐down regimen
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Sequential step‐up/step‐down regimen
Number of subjects: 225
Study: 16797240

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg/day and Aspirin 100 mg/day
Number of subjects: 170

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg/day
Number of subjects: 170
Study: 12771613

Group type: EXPERIMENTAL
Intervention: Enalaprilat
Number of subjects: 40
Study: 10688831

Group type: EXPERIMENTAL
Intervention: Lepirudin (Refludan, bolus: 0.1 mg/kg, infusion: 0.1 mg/kg/h for 5 hours)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 9354207

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg o.m.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.d.
Number of subjects: 24
Study: 8407854

Group type: EXPERIMENTAL
Intervention: d-Amphetamine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 18
Study: 3101396

Group type: EXPERIMENTAL
Intervention: Cyclabil
Number of subjects: 120

Group type: COMPARATOR
Intervention: SH D 386 F
Number of subjects: 120
Study: 29905646

Group type: EXPERIMENTAL
Intervention: Motor-cognitive coordination workplace intervention
Number of subjects: 28

Group type: COMPARATOR
Intervention: Classical workplace health enhancement training
Number of subjects: 28
Study: 26522372

Group type: EXPERIMENTAL
Intervention: Door-Knocking Method (DKM)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional Method (CM)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Door-Knocking Method (DKM) in transgastric puncture group
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional Method (CM) in transgastric puncture group
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Door-Knocking Method (DKM) in transduodenal puncture group
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional Method (CM) in transduodenal puncture group
Number of subjects: 82
Study: 24895815

Group type: EXPERIMENTAL
Intervention: Fast-track (FT) program
Number of subjects: 297
Study: 22117186

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Imagery training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 21084620

Group type: EXPERIMENTAL
Intervention: High criterion for signaling errors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low criterion for signaling errors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ne/ERN
Number of subjects: 0
Study: 18958177

Group type: EXPERIMENTAL
Intervention: Instrumental music training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 16355622

Group type: EXPERIMENTAL
Intervention: Fengbei Huayu recipe (FHR) twice a day for 8 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional hypoglycemic agents and hypotensor
Number of subjects: 72

Group type: COMPARATOR
Intervention: Both groups (FHR and control)
Number of subjects: 72
Study: 14596580

Group type: EXPERIMENTAL
Intervention: Individualized behavioral treatments
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 3
Study: 11279324

Group type: EXPERIMENTAL
Intervention: Captopril (25-75 mg daily)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Fosinopril (10-20 mg daily)
Number of subjects: 52
Study: 8688397

Group type: EXPERIMENTAL
Intervention: Nonclosure of the visceral and parietal peritoneum
Number of subjects: 280

Group type: COMPARATOR
Intervention: Closure of the visceral and parietal peritoneum
Number of subjects: 280
Study: 1885945

Group type: EXPERIMENTAL
Intervention: Rimantadine
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 6337032

Group type: EXPERIMENTAL
Intervention: Clonidine (average 0.24 mg/day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Propranolol (average 105 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30903972

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Continuous Aerobic Training (CAT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: SIT and CAT (combined)
Number of subjects: 53
Study: 28976423

Group type: EXPERIMENTAL
Intervention: Vocational advice service (intervention arm)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Best current primary care (control arm)
Number of subjects: 338
Study: 26374852

Group type: EXPERIMENTAL
Intervention: Right ventricular septal pacing (RVS)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Right ventricular apical pacing (RVA)
Number of subjects: 263
Study: 25217169

Group type: EXPERIMENTAL
Intervention: Individual parent‐only CBT intervention (PCBT, n=18)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Wait-list control (WL, n=13)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combined sample of treated participants
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intent-to-treat sample
Number of subjects: 31
Study: 23094900

Group type: EXPERIMENTAL
Intervention: Group II: 41 ml of levobupivacaine 0.5 % + 1 ml magnesium sulfate (150 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group IV: 41 ml of levobupivacaine 0.25 % + 1 ml magnesium sulfate (150 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group I: 41 ml of levobupivacaine 0.5 % + 1 ml NaCl 0.9 %
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group III: 41 ml of levobupivacaine 0.25 % + 1 ml NaCl 0.9 %
Number of subjects: 80
Study: 20507548

Group type: EXPERIMENTAL
Intervention: Intervention group (questionnaire based intervention programme)
Number of subjects: 741

Group type: COMPARATOR
Intervention: Usual care group (control)
Number of subjects: 741
Study: 18843927

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (added to general body conditioning)
Number of subjects: 30

Group type: COMPARATOR
Intervention: General body conditioning (control group)
Number of subjects: 30
Study: 16137437

Group type: EXPERIMENTAL
Intervention: Adjuvant cyclophosphamide/methotrexate/5-fluorouracil (CMF)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Weekly epirubicin
Number of subjects: 266
Study: 12208801

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nondiabetic patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nondiabetic patients with HF
Number of subjects: 100
Study: 10915232

Group type: EXPERIMENTAL
Intervention: Diltiazem retard (100-200mg once daily)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 8864318

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (200 mg to 1600 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (up to 1600 mg)
Number of subjects: 0
Study: 1636340

Group type: EXPERIMENTAL
Intervention: ThinPrep method
Number of subjects: 2655
Study: 6432325

Group type: EXPERIMENTAL
Intervention: 200 mg of ketoprofen
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1 gm of lysine acetylsalicylate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31174583

Group type: EXPERIMENTAL
Intervention: No drains placed (experimental group)
Number of subjects: 252

Group type: COMPARATOR
Intervention: At least one passive intra-abdominal drain placed (control group)
Number of subjects: 252
Study: 28967099

Group type: EXPERIMENTAL
Intervention: Micronutrients
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93